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Summary The reaction patterns of eight antibodies directed against blood group substances A, B and H,
respectively, against Lewis B antigen, difucosylated carbohydrate antigens (DFCA), gastrointestinal cancer
antigen CA 19-9 (GICA), carcinoma-associated antigen CA-50 and CEA, were studied in 68 rectal
carcinomas using the avidin-biotin-peroxidase method. A pronounced intratumoral antigenic heterogeneity
was revealed for most antigens. It thus became evident that an interpretation based upon small preoperative
biopsies would be inaccurate. The overall proportion of positive carcinoma cells, however, did not vary much
between larger samples taken postoperatively from different regions of the tumours. The intertumoral
antigenic variability was also considerable: nearly all tumours had an individual immunohistochemical profile
according to the proportions of positive cells. Heterogeneous staining patterns were also present within
metastases, and lymph node metastases from the primary tumour in some cases differed completely from each
other. The staining pattern did not correlate with Dukes' stage, and degree of differentiation; the expression
of any individual antigen, or several antigens in combination.
The aggressiveness of a tumour, or individual clones of cells
within a tumour, might be reflected by expression or deletion
of certain cell products involved in e.g. cell growth
regulation, cell to cell interactions and cell differentiation
(Hakomori, 1980; Weinstein et al., 1981). Deletion of ABH
blood group isoantigens has prognostic implications in
carcinoma of the urinary bladder (Limas et al., 1979;
Weinstein et al., 1981). The prognostic relevance of blood
group substances (BGS) in colorectal carcinoma is unknown,
although a prognostic value has been indicated (Wiley et al.,
1981). It has, however, been convincingly demonstrated that
BGS A, BGS B, BGS H and Lewis B antigens are
oncofoetal products of the normal distal colon and rectum,
(Arends et al., 1984a; Atkinson et al., 1982; Cooper et al.,
1978; Cooper & Haessler, 1978; Denk et al., 1974a, b., 1975;
Ernst et al., 1984; Szulman, 1962; Szulman & Marcus, 1973).
Several other antigens like carcinoembryonic antigen (CEA),
gastrointestinal cancer antigen (GICA), carcinoma-associated
antigen (CA-50), and difucosylated carbohydrate antigen
(DFCA) have also been demonstrated in association with
colorectal cancer in a high proportion of cases (Arends et
al., 1984a; Atkinson et al., 1982; Enblad et al., 1986;
Lindholm et al., 1983; Nilsson et al., 1985). The pattern of
CEA expression has recently been reported to correlate
with patient survival (Wiggers et al., 1986), and a possible
prognostic value of GICA immunoreactivity has also been
indicated (Arends et al., 1984a).
The present immunohistochemical study concerns the
expression of BGS and the tumour associated antigens
mentioned above in carcinoma of the rectum and
rectosigmoid. The ultimate aim was to assess the prognostic
significance of the expression patterns of these antigens, both
in preoperative diagnostic biopsies and in postoperative
samples. In the fundamental parts of the study presented
here, the objectives were to: (a) assess the extent of
intratumoral antigenic heterogeneity; (b) determine the
degree of individuality, i.e. intertumoral heterogeneity; (c)
investigate different metastases and compare them with the
primary tumours; and (d) correlate the reaction patterns with
the degree of differentiation and Dukes' stage, respectively.
Materials and methods
Sixty-eight patients, 35 males and 33 females (mean age 66
years, range 39-85), with primary adenocarcinoma of the
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rectum or rectosigmoid, were selected from a randomized
clinical trial comparing pre- and postoperative radiotherapy
(Pahlman et al., 1985). The selected series were all radically
operated patients randomized to postoperative radiotherapy
between October 1980 and April 1983, i.e. during 2.5 years.
One formalin fixed and paraffin embedded sample per
tumour specimen was stained. Lymph node metastases from
11 of the cases were also stained. Beside the selected 68
patients, 9 additional cases were also studied: 2 cases with
liver secondaries and 7 cases sampled at multiple sites (3-7
samples per specimen; average 4). From two of the multiply
sampled tumours, five samples next to the formalin fixed
samples were snapfrozen.
Antibodies
The following 8 antibodies were chosen: mouse monoclonal
antibodies against blood group substances (BGS) A, B and
H, respectively, against difucosylated carbohydrate antigens
(DFCA) (all a generous gift of Dr A. Lundblad, BioCarb
AB, Lund, Sweden), Lewis B antigen (Le B) (Axel Johnson
Instrument AB, Stockholm, Sweden), gastrointestinal cancer
antigen CA 19-9 (GICA) (kindly provided by Dr H.
Koprowski, The Wistar Institute of Anatomy and Biology,
Philadelphia, Pennsylvania, USA), carcinoma associated
antigen CA-50 (a gift of Dr L. Lindholm, Department of
Medical Microbiology, University of G6teborg, Sweden),
and a rabbit polyclonal antibody against CEA (a gift of Dr
A. Hedin, Pharmacia AB, Uppsala, Sweden) (Table I).
Procedures
The avidin-biotin-peroxidase method was used (Vectastain
ABC Kit, Vector Laboratories, Burlingame, California,
USA). Five gm sections were placed on chromium-gelatin
slides, deparaffinized in xylene, rehydrated in decreasing
concentrations of ethanol and rinsed in PBS (0.01 M, pH 7.4,
6min). Endogenous peroxidase was blocked in 0.3%
hydrogen peroxide (30min). Nonspecific background was
reduced by incubation with 1% bovine serum albumin
(15min). The primary antibody was used at the highest
possible concentration which did not cause overstaining or
background staining (30min). Biotinylated anti-mouse IgG
or anti-rabbit IgG served as secondary antibody (dilution
1/200 v/v; 30min) and a peroxidase conjugated biotin-avidin
complex as third step reagent (1/200 v/v; 30min). Staining
was developed in 3-amino-9-etyl-carbazole and 0.002%
hydrgen peroxide (15min), and counterstained in Mayers'
haematoxylin (5min). Primary antibody was regularly
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substituted on parallel sections by 1% bovine serum albumin
in order to exclude non-specific staining. The sensitivity was
ascertained by repeated stainings of positive and negative
tumour specimens.
Evaluation
All staining results were evaluated independently by 3 of the
authors (P.E., B.G. and C.B.). The proportion of the total
sectioned tumour area positively stained (0%/<10%/1-
50%/50-90%/>90%) was estimated. The staining intensity
was not judged since preliminary results showed that
virtually all positive cases were strongly stained. In order to
(quantify' intratumoral variability and to assess the accuracy
of a classification based on preoperative biopsies the stained
sections were divided into areas corresponding to the size of
fictive biopsies, i.e. that could have been taken through a
rigid sigmoidoscope (determined to be 12mm2, mean; range
4-24, from 30 randomly selected biopsies). Practically, the
fictive biopsy areas were scored using an eyepiece with
outlined square markings. In the tumours sampled at
multiple sites the staining patterns of each part were
compared as was the staining of lymph node and liver
secondaries, respectively, with that of the primary tumour.
The ABO blood type was ascertained from the reactions in
endothelium and erythrocytes. Secretor status (Lewis
phenotype) was not assessed.
Results
The staining method was reliable, and classification of
reactions, scored independently by three observers, was
consistent in the majority of cases.
Each antibody had its own characteristic expression.
Besides differences in regional distribution of the antigens,
differences in cellular localisation were also noted.
Cytoplasmic staining dominated for BGS A, BGS B, BGS
H, DFCA, Le B and CA-50; membranous and intraluminal
for CEA and GICA. The estimated proportions of cells
positive for the different antigens are presented in Table
IIA-G. Table IIA presents the expression of compatible
BGS, i.e. BGS A expression in blood type A patients, BGS
B expression in blood type B patients and BGS H expression
in blood type 0 patients. Patients with blood type AB were
classified according to the highest proportion of positive cells
expressing either BGS A or BGS B. The expression of BGS
H is also presented separately (Table IIB), since BGS H is a
precursor of BGS A and BGS B and thus not only expressed
in blood type 0 patients. Expression of 'incompatible' BGS
was seen in 9 tumours; between < 10% and up to 50-90%
of the tumour cells expressed BGS B weakly (5 patients with
blood type A and 4 patients with blood type 0). This may
partly be explained by a weak BGS A affinity of the anti-B
antibody (Table I).
Intratumoral antigenic heterogeneity
All tumours showed heterogeneous staining; none of the
tumours was either totally positive or totally negative for
any antigen studied. The proportion of positive cells as well
as the staining pattern (foci of positive cells, disseminated
positive cells or combinations thereof) varied between
different parts of the sections and between samples from
different tumour regions (Table III, Figure 1). The
heterogeneity was equally prominent in peripheral and
central areas of the tumours. A similar heterogeneity was
also seen in the snapfrozen sections (data not illustrated).
The proportions of positive cells in the fictive preoperative
biopsies varied considerably; for several of the antibodies
from 0-100% within the same section. The overall
proportion of positve cells did not, however, vary much
between the larger samples (sections of approximate size
10 x 1Omm) taken from different regions of the surgical
specimens (Table III, Figure 1).
Intertumoral antigenic heterogeneity or individuality
A considerable divergency in antigenic expression was seen
between the tumours. The proportion of positive cells,
according to the defined categories, varied between 0%-
>90% for all antigens, except for CEA (Table II). If all
antigens were accounted for in an immunohistochemical
profile 64 different phenotypes were recognized from the
defined proportions of positive cells. If the classification was
restricted to 'negative' (0% and < 10%), 'heterogeneous'
(10-50% and 50-90%) and 'positive' (>90%), 56 different
phenotypes were seen. The cases without a phenotype of
their own were not clustered to one or a few phenotypes.
Antigenic heterogeneity in metastases
There was no consistent staining pattern in the lymph node
metastases and liver secondaries, suggestive of a phenotype
with high metastatic potential. Heterogeneous staining
patterns occurred within the metastases, regardless of the
antigenic state on the primary tumour (heterogeneous or
predominantly homogeneous). Lymph nodes from the same
primary tumour could differ completely from each other
(Table IV, Figure 1).
Table I Survey of monoclonal antibodies used
Antibody Affinity References
Anti-A Mono- and difucosylated type I and Chen & Kabat, 1985
type II A antigen (BGS A).
Anti-B B antigen (BGS B) c
Anti-H Mono- and difucosylated type II H antigen c
(BGS H).
Anti-Le B Lewis B antigen d
(Le B).
Anti-DFCA Difucosylated type I and type 11 chain antigens Enblad et al., 1986
(DFCA).
19-9 Gastrointestinal cancer antigen (GICA) or CA 19-9 Magnani et al., 1981
(Sialoganglioside).
C-50 Carcinoma-associated antigen CA-50 Lindholm et al., 1983
(Sialoganglioside). Nilsson et al., 1985
Anti-CEAb Carcinoembryonic antigen (CEA). Hammarstrom et al., 1977
aReacts strongly (+ + + +) with B antigen, and weakly (+) with A antigen in agglutination tests;
bPolyclonal; 'Specification by BioCarb AB, Lund, Sweden; dSpecification by Axel Johnson Instrument AB,
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Table IIA Compatible - BGSa expression related to Dukes' stage
and degree of differentiation
Dukes' stage Differentiation
Proportion of
Positive cells A B C well moderately poorly Total
>90% 9 13 20 7 28 7 42
50-90% 3 3 2 8 8
10-50% 2 6 1 5 2 8
<10% 3 1 1 2 1 4
0% 2 1 3 1 4 1 6
Total 14 22 32 10 47 11 68
aPatients with blood type AB were classified according to the
highest proportion of positive cells expressing BGS A or B.




Positive cells A B C well moderately poorly Total
>90% 11 15 24 10 31 9 50
50-90% 2 2 3 6 1 7
10-50% 1 2 2 5 5
<10% 2 2 3 1 4
0% 1 1 2 2
Total 14 22 32 10 47 11 68




Positive cells A B C well moderately poorly Total
>90% 10 11 16 8 27 5 40
50-90% 3 4 10 1 11 5 17
10-50% 1 1 3 1 4 5
<10% 3 1 4 4
0% 2 1 1 2
Total 14 22 32 10 47 11 68




Positive cells A B C well moderately poorly Total
>90% 8 8 17 6 22 5 33
50-90% 6 6 2 8 2 12
10-50% 3 3 4 1 6 3 10
< 10% 3 5 4 1 10 1 12
0% 1 1 1
Total 14 22 32 10 47 11 68




Positive cells A B C well moderately poorly Total
>90% 7 14 16 6 26 5 37
50-90% 2 4 7 3 5 5 13
10-50% 2 2 6 1 8 1 10
<10% 3 1 4 4
0% 2 2 4 4
Total 14 22 32 10 47 11 68




Positive cells A B C well moderately poorly Total
>90% 1 7 5 2 8 3 13
50-90% 2 4 3 2 6 1 9
10-50% 5 3 13 3 14 4 21
< 10% 4 5 5 2 10 2 14
0% 2 3 6 1 9 1 11
Total 14 22 32 10 47 11 68




Positive cells A B C well moderately poorly Total
>90% 13 22 31 10 46 10 66












Figure 1 Schematic illustration of antigenic heterogeneity found
in rectal carcinomas and their secondaries. (Large squares
correspond to the usual size of samples from surgical specimens
and small squares to the size of (fictive) biopsies taken through a
rigid sigmoidoscope).506 P. ENBLAD et al.
Table III Proportion of positive carcinoma cells (%) in large samples from surgical specimens and in fictive preoperative biopsies from 5 rectal
carcinomas
Antigens: A B H Le B DFCA CA-SO GICA CEA
Case No: 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5
Samples (%)
0 3a 4 13 3 4 3 3 2 4
<10 4 1 1 4 1 3 24 3
10-50 2 3 2 1 34 2 3 1 5
50-90 2 2 3 2 11 1 1 1 1 2 2 3 31 3
>90 3 1 23 32 3 63 6 3 51 1 33 14 7
Antigens A B H Le B DFCA CA-SO GICA CEA
Case No: 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5
Preoperative
Biopsies (%)
0 12 1030 910 1224 301 3 4 51 1 96 12 7 12 2822 17
<10 3 2 7 1 1 1 49 1 10 22 1 52 8 4
10-50 1 3 6 6 1 4 14 15 56 2 31 7 13 141 3 7
50-90 13 3 7 6 72 3 54 4 4 6 5 5 4 15 1 1 4
>90 10 4 4 6 1012 1522 1910 3 117 101 13 4 20 11 9 1230 21
aNumber of samples/biopsies allocated to the defined proportions of positive cells.
Table IV Antigenic heterogeneity in rectal carcinoma lymph node
metastases (Two representative cases)
Proportion ofpositive carcinoma cells(%
Lymph node metastases
Antigens Primary tumour 0 <10 10-50 50 90 >90
CASE 1
BGSA >90 la 5
BGSB <10 2 3 1
BGSH >90 4 2











CA-SO 10-SO 1 3 2
GICA 0 4 1 1
CEA >90 6
aNumber of lymph nodes
Correlation with degree of differentiation and Dukes' stage
The staining patterns did not correlate with Dukes' stage
and degree of differentiation (as judged from the most
poorly differentiated area); the expression of any individual
antigen (Table IIA-G), or of several antigens in combination
(data not illustrated). This was true even if the staining
results were divided into a predominantly homogeneous
(0%, <10% and >90%) and a predominantly hetero-
geneous (10-50% and 50-90%) pattern (data not separately
illustrated). Nor did heterogeneously differentiated tumours
disclose that the expression varied with the local degree of
differentiation.
Discussion
The most striking observation in the present study was the
extreme intratumoral antigenic heterogeneity found in rectal
carcinoma. Earlier immunohistochemical studies ofmalignant
tumours have mainly focused on the detection of various
tumour maker antigens with very little attention paid to
whether the staining was homogeneously or heterogeneously
distributed. However, an antigenic heterog-eneity in
colorectal carcinoma has been mentioned in a fe~w pre'vious
investigations (Arends et at., 1984a, b; Daar & Fabre, 1983;
Rognum et at., 1983), and the heterogeneous nature is
further substantiated by reports concerning e.g. mor-
phology, growth rate, karyotype, DNA content, cloning
eff'iciency, tumorigenicity in nude mice, and chemo-
therapeutic response (Brattain et at., 1977, 1979, 1981; Chen
et at., 1982; Dexter et at., 1979; Enblad et at., 1985; Kimball
et at., 1978; Kimball & Brattain, 1980; Petersen et al., 1979a,
b; Pretlow et at., 1977).
The precise mechanisms behind antigenic heterogeneity are
uncertain. Variations in the expression of various
compounds during the cell cycle, unstable genotypes and/or
unstable phenotypes have been suggested (Arends et at.,
1984b; Edwards 1985; Fidler, 1978; McCormack, 1984;
Nowell, 1976; Olsson et at., 1984). The observation of more
or less large foci of antigenically defilned cancer cells suggests
that, at least in some cases, coexistence of several clones
might be one of the correct explanations. Since heterogeneity
was also seen in metastasis it may be suggested either that
-new clones arise very frequently in this heteroploid cancer
(Enblad et at., 1985; Petersen et at., 1979a, b) or that
metastases do not develop from genetically homogeneous
seeds but rather from small populations of already
heterogeneous cells.
Interesting questions are also whether the different
heterogeneous and predominantly homogeneous antigenic
patterns, respectively, reflect stages in the dynamics of clonal
evolution during local tumour progression (Nowell, 1976;
Rognum et at., 1983), and whether some antigenically
def'ined populations are more capable of metastasizing than
others. Since the advanced tumours did not show a
consistent staining pattern, and since there was no consistent
pattern within the metastasis, the present data do not
support these considerations.
The considerable degree of intertumoral heterogeneity
found may partly be explained by the unique genetic
properties of each individual. For example, the expression of
blood group substances was shown to be determined by the
blood type of the patients. Similar, but unknown inherited
determinants may also regulate the expression of other
antigens. Moreover, the genetic changes involved in the
malignant transformation itself may be unique for every
individual tumour resulting in an extreme phenotypicANTIGENIC HETEROGENEITY IN RECTAL CARCINOMA 507
individuality. Finally, the possible importance of environ-
mental conditions may not be ignored regarding the
appearance of different individual phenotypes, as well as
phenotypic diversity within individual tumours.
Because of the intratumoral antigenic heterogeneity found
it is evident that an interpretation of rectal carcinomas based
upon preoperative biopsies, using this panel of antibodies,
would be inaccurate in many cases (Table III, Figure 1).
This conclusion is further substantiated by the fact that in a
few cases where multiple preoperative biopsies were
examined, a variability between 0% and 100% positive cells
were seen for certain antigens (Enblad et al., unpublished
observation). Furthermore, the heterogeneity may complicate
the use of monoclonal antibodies in tumour imaging and
therapy. Thus, monoclonal immunotherapy devices may be
more efficient in antigenically less heterogeneous cancers.
However, immunohistochemical screening may help to
identify potentially the most appropriate antibodies for in
vivo applications, as e.g. anti-CEA in the present study,
which had a broad spectrum of reactivity both in primary
tumours and metastasis.
An immunohistochemical classification based upon
samples much larger than preoperative biopsies seems to be
more accurate (Table III). The staining patterns did not
correlate with degree of differentiation and Dukes' stage
(Table II), which so far gives the best prediction of clinical
course. However, the prognostic relevance may not be
definitely assessed until the patients have been followed for
longer time periods and the immunohistochemical profiles
related to patient survival.
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